Figure 1.

CSN4 is a novel binding partner for sGCα1 in prostate cancer cells. LNCaP and CWR-22Rv1 cell extracts were subjected to IP (panel A) using an (A) anti-sGCα1 antibody or (B) anti-CSN4 antibody. IgG was used as a control. Western blotting was used to measure sGCα1 and CSN4 proteins. C, LNCaP and CWR-22Rv1 cells were subjected to immunocytochemistry using anti-sGCα1 and anti-CSN4 antibodies to measure subcellular localization of endogenous sGCα1 and CSN4. 4′6-diamidino-2-phenylindole (DAPI) stains nuclei. Ab, antibody.